VERTEX PHARMACEUTICALS INC

Vertex Pharmaceuticals Incorporated (ticker VRTX, CUSIP 92532F100) is a leading U.S. biotechnology company whose scientific platform has produced transformative therapies for cystic fibrosis, sickle cell disease, and, most recently, a selective type 1 diabetes treatment under regulatory review. Vertex's 13F institutional base for Q2 2026 is highly concentrated: nine institutions reported $15.38M in aggregate, of which MassMutual Private Wealth & Trust alone accounts for $14.10M and 28,385 shares — 91.7% of reported 13F ownership. MassMutual trimmed 341 shares during the quarter (from 28,726 to 28,385) but its reported value rose $1.27M, indicating VRTX stock appreciated materially during Q2 and that MassMutual's trimmed position is a rounding rebalance rather than a signal of reduced conviction. Versant Capital Management reduced by 11 shares from 1,066 to 1,055, a further minor rebalance. Hilltop National Bank added 31 shares (valueChange +$29K). Eastern Bank reduced 57 shares (-$10K) and Trust Co of the South reduced 100 shares (-$2.8K). Cedar Mountain, Kozak, and CX all held flat. Noble Wealth opened a new token position at $1,490 and 3 shares. No meaningful liquidation or addition occurred among the larger holders.